Type1diabetes Clinical Trial
— MAIT-DT1Official title:
Crosstalk Between Mucosal-Associated Invariant T Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children
To investigate in a prospective way changes in Mucosal-Associated Invariant T (MAIT) cells frequency, phenotype and function in link with the gut microbiota, gut integrity and the presence of Coxsackie virus B in two cohorts of pediatric patients: patients with a high genetic risk of type 1 diabetes and pediatric patients with recently diagnosed T1D by comparison with control subjects Tasks: 1. To measure blood MAIT cells frequency, phenotype and function in the three cohorts 2. To analyze gut microbiota and the presence of Coxsackie B enterovirus (CVB) and their impact on MAIT cell function 3. To evaluate gut integrity and analyze the gut mucosa 4. To integrate all the data obtained with T1D development and evolution
Status | Recruiting |
Enrollment | 180 |
Est. completion date | October 1, 2025 |
Est. primary completion date | October 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 15 Years |
Eligibility | Inclusion Criteria: Recent onset group - age > 12 months and < 15 years - recently diagnosed type 1 diabetes according ISPAD criteria At risk subjects: - age > 12 months and < 15 years - siblings of type 1 diabetic patient - HLA DR3 and DR4 positive Control subjects: - age > 12 months and < 15 years - no HLA associated with high risk type 1 diabetes - no antibodies against pancreas antigenes Control subjects for UGI endoscopy: - age > 12 months and < 15 years - suspicion of coeliac disease or gastritis Exclusion Criteria: For all groups: - no health care insurance - parents or tutors unable to sign the consent - personal history of autoimmune disease and/or inflammatory disease except from T1D for RD and CE groups - use of corticosteroids during the month before inclusion - pregnant subjects - medical contraindication of anesthetic topics For control subjects for UGI endoscopy control and Recent onset-endoscopy group: - age below 8 years for Recent onset-endoscopy group - age below 4 for UGI endoscopy control group - cardiac or respiratory insufficiency, cardiac rhythm disorders, coagulation disease, patients treated with anticoagulant or antiaggregant drug - history of allergy to anesthetic drug |
Country | Name | City | State |
---|---|---|---|
France | Hopital privé d'Antony | Antony | |
France | Hopital Necker enfants malades | Paris |
Lead Sponsor | Collaborator |
---|---|
Institut National de la Santé Et de la Recherche Médicale, France | Assistance Publique - Hôpitaux de Paris, FRANCE, Institut National de la Recherche Agronomique, Tampere University |
France,
Rouland M, Beaudoin L, Rouxel O, Bertrand L, Cagninacci L, Saffarian A, Pedron T, Gueddouri D, Guilmeau S, Burnol AF, Rachdi L, Tazi A, Mouriès J, Rescigno M, Vergnolle N, Sansonetti P, Christine Rogner U, Lehuen A. Gut mucosa alterations and loss of segmented filamentous bacteria in type 1 diabetes are associated with inflammation rather than hyperglycaemia. Gut. 2022 Feb;71(2):296-308. doi: 10.1136/gutjnl-2020-323664. Epub 2021 Feb 16. — View Citation
Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C, Cagninacci L, Kiaf B, Oshima M, Diedisheim M, Salou M, Corbett A, Rossjohn J, McCluskey J, Scharfmann R, Battaglia M, Polak M, Lantz O, Beltrand J, Lehuen A. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat Immunol. 2017 Dec;18(12):1321-1331. doi: 10.1038/ni.3854. Epub 2017 Oct 9. Erratum in: Nat Immunol. 2018 Jun 7;:. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | blood MAIT cells frequency | percentage of MAIT cells in the peripheral blood | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | MAIT cells membrane markers analysis | CD25 positive cells in percentage, CD69 positive cells in percentage, CD44 positive cells in percentage, PD1 positive cells in percentage , KLRG1 positive cells in percentage, TIM3 positive cells in percentage | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | Cytokines production in the cytoplasm of the MAIT | Antibodies against IL- 2 , IFN-y, TNF-a, IL-2, IL-10, IL-13, IL-17 and granzyme B expressed in Cells % | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | MAIT cell ligands measurements | Percentage of MAIT cells activated in vitro when cultivated in presence of subject stool sample | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | Presence of CVB in the stools | CVB specific ARN detection in subjects stools samples by qPCR | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | Blood immunoglobulins against CVB infection statu | Specific antibodies (Ig G) against CVB measurements in patients blood sample | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | Measurement of intestinal gut mucosal permeability | Assessing the permeability of the intestine using the Lactulose-Mannitol test. Concentration of lactulose and manitol in subjects urine samples in mg/dl | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | Evaluation of gut mucosal integrity | qPCR for the expression of key epithelial molecules and cytokines on gut samples | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) | |
Secondary | 16 S sequencing in the Subjects stools | The 16S rRNA gene sequencing will be used for the classification and identification of microbes species in subjects stools. Each species will be identified and quantified as a percentage of the total number of identified species in the stools. | Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03886974 -
Transition to Adult Care in Type 1 Diabetes
|
||
Completed |
NCT05620251 -
Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
|
||
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05078658 -
Low-carbohydrate Diet in Children With Type 1 Diabetes
|
N/A | |
Not yet recruiting |
NCT06018324 -
CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
|
||
Withdrawn |
NCT03736083 -
Introducing CGM at Type 1 Diabetes Diagnosis
|
N/A | |
Completed |
NCT03177096 -
Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes
|
N/A | |
Completed |
NCT04172077 -
Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
|
||
Recruiting |
NCT04950634 -
Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
|
||
Completed |
NCT04450745 -
Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients
|
N/A | |
Completed |
NCT03165786 -
A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes
|
N/A | |
Terminated |
NCT04028960 -
IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
|
Phase 2 | |
Recruiting |
NCT05324488 -
Diabetes Registry Graz for Biomarker Research
|
||
Completed |
NCT02984709 -
Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes
|
N/A | |
Completed |
NCT02984514 -
Brown Adipose Tissue in Type 1 Diabetes
|
N/A | |
Recruiting |
NCT06372392 -
Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps
|
N/A | |
Recruiting |
NCT03311516 -
New Insulin Therapy by Multiwave Bolus
|
N/A | |
Recruiting |
NCT05973799 -
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
|
N/A | |
Completed |
NCT03711656 -
Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques
|
N/A | |
Recruiting |
NCT05737654 -
The Effect of Exercise on Metabolic Parameters, Anthropometric Measurement Values and Quality of Life
|
N/A |